| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.04B | 2.71B | 2.51B | 3.90B | 9.90B | 5.77B |
| Gross Profit | 127.66M | 555.56M | -50.28M | 113.52M | 1.25B | 980.32M |
| EBITDA | -59.80M | 295.14M | -145.86M | -325.93M | 581.55M | 1.09B |
| Net Income | -1.41B | -1.24B | -563.97M | -912.78M | 228.33M | 98.74M |
Balance Sheet | ||||||
| Total Assets | 56.83B | 57.20B | 56.35B | 57.39B | 61.07B | 67.52B |
| Cash, Cash Equivalents and Short-Term Investments | 171.08M | 158.10M | 152.22M | 189.51M | 556.87M | 1.65B |
| Total Debt | 22.59B | 22.79B | 22.18B | 21.25B | 20.95B | 23.52B |
| Total Liabilities | 44.63B | 44.83B | 42.57B | 43.01B | 45.64B | 52.41B |
| Stockholders Equity | 9.70B | 9.93B | 11.17B | 11.73B | 12.71B | 12.49B |
Cash Flow | ||||||
| Free Cash Flow | 632.07M | 678.26M | 452.11M | 413.47M | 4.07B | 4.67B |
| Operating Cash Flow | 630.31M | 679.53M | 512.92M | 606.31M | 4.35B | 4.94B |
| Investing Cash Flow | 105.81M | 146.72M | 58.95M | -305.41M | 184.15M | -2.78B |
| Financing Cash Flow | -770.21M | -830.50M | -627.40M | -630.90M | -5.65B | -1.11B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
47 Neutral | HK$233.52M | -5.48 | -5.13% | ― | -76.39% | -1142.86% | |
41 Neutral | HK$546.66M | -0.36 | -13.99% | ― | -0.38% | -296.42% | |
41 Neutral | HK$134.37M | -0.05 | -35.96% | ― | -5.63% | -36.30% | |
40 Underperform | HK$139.77M | -0.01 | ― | ― | -70.13% | -16.86% | |
40 Underperform | HK$289.99M | -0.17 | -34.31% | ― | -63.41% | 77.97% |
Glory Health Industry Limited has appointed Mr. Wang Shiyu as an independent non-executive director, chairman of the internal control committee, and a member of the audit committee, effective December 1, 2025. Mr. Wang brings extensive experience in investment banking, mergers and acquisitions, and corporate globalization, which is expected to strengthen the company’s governance and strategic direction.
Glory Health Industry Limited has announced the composition of its board of directors and the establishment of four committees to oversee various aspects of its operations. The board comprises both executive and independent non-executive directors, with Zhang Zhangsun serving as the chairman. This announcement highlights the company’s commitment to structured governance and operational oversight, which may enhance its industry positioning and stakeholder confidence.
Glory Health Industry Limited has provided an update on its efforts to address a disclaimer of opinion issued by its auditors regarding its financial statements for the year ended December 31, 2024. The company has completed the Xi’an Guorui Financial Center Building, which is expected to aid in sales and cash flow recovery. Additionally, a significant loan extension has been approved, and the company is actively seeking buyers for several projects to ease liquidity problems and reduce debt. The management is committed to achieving debt restructuring and asset disposal goals within 2025.